Search for drugs:
Typing the drug name to query
FOSTAMATINIB
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At 2 times the maximum recommended dose, TAVALISSE did not prolong the QT interval to a clinically relevant extent.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- B02BX09 - fostamatinib
- B02BX0 -
- B02BX - Other systemic hemostatics
- B02B - VITAMIN K AND OTHER HEMOSTATICS
- B02 - ANTIHEMORRHAGICS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:FOSTAMATINIB
Active Ingredient UNII:SQ8A3S5101
Drugbank ID:DB12010
PubChem Compound:11671467
CTD ID:C523665
CAS Number:901119-35-5
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.